Pure Global
NCT06417099

Efficacy of Dihydroartemisinin for Treating PCOS

Therapeutic Efficacy of Dihydroartemisinin in Patients With Polycystic Ovary Syndrome
Shanghai Zhongshan Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Polycystic Ovary Syndrome
Drug/Device/Intervention
Dihydroartemisinin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shanghai Zhongshan Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
May 01, 2025
Enrollment
30 participants
Primary outcome

Recovery of regular menses

Summary

The primary research hypothesis of this study is that dihydroartemisinin is effective in
 restoration of regular menstrual cycles of PCOS subjects who meet at least two of three
 Rotterdam Criteria. Secondary research hypotheses include: dihydroartemisinin is also
 effective in reducing androgen, total immature follicles, and anti-Mullerian hormone.

ICD-10 classifications
Polycystic ovarian syndromeOvarian dysfunction, unspecifiedOvarian dysfunctionOther ovarian dysfunctionNeoplasm of uncertain or unknown behaviour: Ovary
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06417099
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06417099 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shanghai Zhongshan Hospital and is currently Recruiting. The study focuses on Polycystic Ovary Syndrome. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.